• 36
Reading Time: 6 minutes

Diabetes-related foot ulcers remain one of the most common and costly complications of diabetes, and many heal slowly despite good standard care: debridement, offloading, infection control, and restoration of blood flow. That gap has encouraged interest in adjunctive therapies, and ozone therapy is one of the more widely promoted options. This post reviews what systematic reviews, meta-analyses, and current international guidance from the past decade actually show about ozone for diabetic foot ulcers.

What Is Ozone Therapy?

Medical ozone is a mixture of ozone (O3) and oxygen produced by a generator. In wound care it is applied in several ways: as a gas delivered to the limb inside a sealed bag or boot, as ozonated oils or water applied to the wound, by local injection around the ulcer, or systemically through so-called autohemotherapy. Proposed mechanisms include direct antimicrobial action through oxidation of bacterial cell membranes, stimulation of antioxidant defences, improved local oxygen delivery, and release of growth factors that support tissue repair. These mechanisms come largely from laboratory and animal work.

The Cochrane Review: Too Little Evidence to Draw Conclusions

The Cochrane review by Liu and colleagues (2015) identified only three randomized controlled trials, with 212 participants in total. Risk of bias was judged high in two trials and unclear in the third. In one trial of 101 participants comparing ozone with antibiotics over 20 days, ozone was associated with a greater reduction in ulcer area and a hospital stay about eight days shorter, but there was no significant difference in the number of ulcers healed (risk ratio 1.10, 95% CI 0.87 to 1.40). When ozone was added to usual care in the other two trials (111 participants), there was no statistically significant difference in ulcer area, ulcers healed (RR 1.69, 95% CI 0.90 to 3.17), adverse events, or amputation, and the confidence intervals were very wide. The authors concluded that, with three small trials of unclear methodology, they were unable to draw firm conclusions about effectiveness, and rated the overall evidence as low quality.

Newer Meta-Analyses: Signals, but Not on Complete Healing

Later reviews have pooled a larger, though still modest and overlapping, body of trials. Wen and colleagues (2022), in a systematic review of ozone for chronic refractory wounds and ulcers including 12 randomized trials, reported greater wound-area reduction and a lower amputation rate with ozone (RR 0.36, 95% CI 0.24 to 0.54). However, they found no improvement in the proportion of participants whose wounds healed completely and no reduction in length of hospital stay, and called for more high-quality randomized trials.

Izadi and colleagues (2024) pooled 11 studies with 960 patients with diabetic foot ulcers. Ozone was associated with smaller ulcer size, shorter healing time, shorter hospital stay, and fewer amputations (RR 0.46, 95% CI 0.30 to 0.71). Yet the authors concluded that ozone’s effect did not differ from standard treatment for complete ulcer resolution, and they highlighted substantial heterogeneity among the included studies. A separate review by Lima e Silva Filho and colleagues (2024) found only six of 61 identified studies eligible; it described higher healing rates and shorter hospital stays but noted a considerable risk of bias and stated that better-designed research is needed to validate the results.

Two points matter when interpreting these findings. First, these meta-analyses draw from many of the same small trials, so they should not be read as independent confirmation of one another. Second, the outcome that matters most to patients and clinicians, complete wound closure, has consistently failed to show a clear benefit, while the positive signals come mainly from surrogate measures such as wound area and from trials at high risk of bias. Reported adverse events have been few, but safety data are limited by small trial sizes.

What International Guidelines Recommend

The International Working Group on the Diabetic Foot (IWGDF) 2023 guideline on interventions to enhance healing of diabetes-related foot ulcers (Chen and colleagues) addressed ozone alongside other therapeutic gases. Its recommendation is direct: do not use other gases, including cold atmospheric plasma, ozone, nitric oxide, and carbon dioxide, in comparison to standard of care for wound healing in people with diabetes-related foot ulcers. The recommendation is graded as strong, based on low-certainty evidence. The guideline notes that none of the studies on these gases were judged to be at low risk of bias, and that the ozone trials were either at high risk of bias, failed to show a demonstrable effect, or both. Hyperbaric and topical oxygen are considered separately in the guideline.

Key Takeaways

Ozone therapy has a plausible biological rationale and some trials report faster wound shrinkage, shorter hospital stays, and fewer amputations. However, the evidence base consists of small, heterogeneous studies with substantial risk of bias, and pooled analyses have not shown that ozone increases the proportion of ulcers that heal completely. The Cochrane review could not draw firm conclusions, and the IWGDF 2023 guideline recommends against using ozone for wound healing in diabetes-related foot ulcers. Healing continues to depend on the established foundations of care: pressure offloading, sharp debridement, management of infection, assessment and treatment of peripheral artery disease, and metabolic control. Adequately powered, blinded randomized trials would be needed before ozone could be considered an evidence-based adjunct.

References

  • Liu J, Zhang P, Tian J, Li L, Li J, Tian JH, Yang K. Ozone therapy for treating foot ulcers in people with diabetes. Cochrane Database of Systematic Reviews. 2015;(10):CD008474.
  • Wen Q, Liu D, Wang X, et al. A systematic review of ozone therapy for treating chronically refractory wounds and ulcers. International Wound Journal. 2022;19(4):853–870.
  • Izadi M, Jafari-Oori M, Eftekhari Z, et al. Effect of ozone therapy on diabetes-related foot ulcer outcomes: a systematic review and meta-analysis. Current Pharmaceutical Design. 2024;30(27):2152–2166.
  • Lima e Silva Filho M, Paggiaro AO, Carvalho VF, Gemperli R. Ozone therapy as a treatment for diabetic foot ulcers: a systematic review and meta-analysis. Journal of Wound Care. 2024;33(12):958–967.
  • Chen P, Vilorio NC, Dhatariya K, et al. Guidelines on interventions to enhance healing of foot ulcers in people with diabetes (IWGDF 2023 update). Diabetes/Metabolism Research and Reviews. 2024;40(3):e3644.

Comments

comments

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.